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Abstract
Purpose: To demonstrate the feasibility of fast Monte Carlo (MC) based inverse biological
planning for the treatment of head and neck tumors in spot-scanning proton therapy. Methods:
Recently, a fast and accurate Graphics Processor Unit (GPU)-based MC simulation of proton
transport was developed and used as the dose calculation engine in a GPU-accelerated IMPT
optimizer. Besides dose, the MC can simultaneously score the dose-averaged linear energy transfer
(LETd), which makes biological dose (BD) optimization possible. To convert from LETd to BD,
a simple linear relation was assumed. Using this novel optimizer, inverse biological planning was
applied to four patients, including two small and one large thyroid tumor targets, and one glioma
case. To create these plans, constraints were placed to maintain the physical dose (PD) within 1.25
times the prescription while maximizing target BD. For comparison, conventional IMRT and IMPT
plans were also created using Eclipse (Varian Medical Systems) in each case. The same critical
structure PD constraints were used for the IMRT, IMPT and biologically optimized plans. The BD
distributions for the IMPT plans were obtained through MC re-calculations. Results: Compared
to standard IMPT, the biologically optimal plans for patients with small tumor targets displayed
a BD escalation that was around twice the PD increase. Dose sparing to critical structures was
improved compared to both IMRT and IMPT. No significant BD increase could be achieved for
the large thyroid case, and when the presence of critical structures mitigated the contribution of
additional fields. The calculation of the biological optimized plans can be completed in a clinically
viable time (below 30 minutes) on a small 24-GPU system. Conclusion: By exploiting GPU
acceleration, MC-based, biologically optimized plans were created for small-target tumor patients.
This optimizer will be used in an upcoming feasibility trial on LETd painting for radio-resistant
tumors.
1. Introduction
The in-vivo radio-resistance of human tumor cells varies greatly. Some tumor types have
high degrees of radio-resistance both in-vitro and in clinical experience. These tumors include
glioblastoma multiforme [1], poorly differentiated/anaplastic thyroid cancer [2], unresectable sali-
vary tumors [3], certain head and neck sarcomas [4], and head and neck squamous cell carcinomas
that recur after prior radiotherapy [5]. The lack of durable radiation response within these tumor
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types poses a significant clinical challenge. Patients with these tumors have some of the worst
disease-free and overall survival statistics among all cancer patients.
Double-strand breaks generated by particle tracks with high Linear Energy Transfer (LET) are
thought to be more complex and more difficult to repair [6]. The treatment of salivary tumors,
thyroid malignancies and glioblastoma with neutrons and carbon ions has demonstrated increased
local control when compared with historical controls. For protons, the LET and Relative Biological
Effectiveness (RBE) vary along particle trajectories, increasing towards track ends. Although an
absolute prediction of RBE values is very difficult, the relationship between RBE and LET can be
approximated as linear. Proton treatment plans that exploit this rise in LET to deliver increased
biological dose (BD) to the target can potentially result in improved outcomes for radio-resistant
tumors.
To estimate BD distributions, one requires the dose-averaged LET (LETd). The most reliable
way to calculate LETd is through Monte Carlo (MC) simulations, since contributions from sec-
ondary particles produced in non-elastic proton-nucleus interactions can be significant. Previous
authors have employed a variety of methods to elevate the target BD [7, 8]. BD escalation methods
that involve the use of MC techniques are usually of the forward-planning type. Furthermore, they
are not clinically viable because CPU-based MC calculations are overly time-consuming. To the
best of our knowledge, MC-calculated LETd distributions have not yet been directly incorporated
in inverse planning for proton therapy. Compared to other BD escalation methods, MC-based
inverse biological planning is not only expected to be more accurate, but also to produce plans
with more conformal and homogeneous BD, and with better normal tissue sparing.
The goal of this work is to demonstrate clinically-applicable, MC-based inverse biological plan-
ning in pencil-beam scanning proton therapy. The target BD is escalated in comparison with con-
ventional Intensity Modulated Proton Therapy (IMPT) planning, while keeping the same Organ-
At-Risk (OAR) constraints and restricting physical dose (PD) hotspots to within 25% or so of the
prescription dose. Two pieces of software that made such plans calculable in less than 30 minutes
are: (a) a GPU-based proton transport MC [9], and (b) a GPU-based IMPT optimizer that uses
pre-calculated, spot-wise LETd and PD maps from the MC [10]. The applicability and limitations
of the method is illustrated with four cases. The focus is on head-and-neck tumors, although other
sites can benefit as well.
2. Methods and materials
2.1. GPU-accelerated MC
Recently, our group has developed a very fast and accurate proton transport MC for the GPU,
with net computational times of ∼20s for 1×107 proton histories [9]. This GPU-based MC includes
a Bertini cascade simulation [11] for handling non-elastic interactions on an event-by-event basis,
and is thus capable of performing accurate LETd computations. The MC model for computing
the PD was extensively verified with TOPAS version beta-6 [12] and Geant4.9.6. The LETd
computations were also compared with TOPAS predictions. As an example, Figure 1 shows the
PD and LETd calculations from TOPAS and our in-house MC for a head-and-neck patient. The
3D-gamma [13] pass rate at 2%/2mm was above 98% for the dose calculation.
2.2. GPU-based optimizer
In addition, our group has built a fast GPU-accelerated IMPT optimizer [10], which uses the
previously-described MC as the dose calculation engine. On a 24-GPU system, this optimizer can
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Figure 1: TOPAS LETd and physical dose calculations are shown in the top and bottom left panels, respectively.
The corresponding computations from the in-house GPU-based MC are shown on the right.
3
generate IMPT plans within a clinically viable time frame (i.e. within 30 minutes). Because they
are MC-based, these plans are not adversely affected by inaccuracies due to tissue heterogeneities.
The IMPT optimizer was slightly modified for the purposes of this work, by allowing the input
of LETd maps, implementing voxel-wise BD estimates (see Equation 1 below), and modifying the
cost function.
2.3. LETd to biological dose conversion
To simplify the BD calculation during the optimization process, a simple linear relationship
between LETd and BD was assumed:
BD = 1.1× (a · LETd + b) (1)
where a=0.05 µm/keV and b=0.95. PD and LETd are in units of Gy and keV/µm, respectively.
These coefficients were chosen so that Equation 1 roughly corresponds to a linear-quadratic model
with α/β = 3 Gy. With these values of a and b, Equation 1 yields a dependence of RBE on
LETd that is close to previously published models from Carabe et al [14], Wedenberg et al [15]
and McNamara et al [16], which were derived from fits to in-vitro cell survival data. A dose per
fraction of 2 Gy was assumed when comparing Equation 1 to these models. The post-optimization
BD was evaluated by using the published models instead of Equation 1.
The term in brackets is the deviation from the conventional 1.1×PD. Suggestive evidence for a
linear relation between RBE and LET can be found in references [14, 17]. The same linear relation
was naively assumed to be valid for all cell kinds. As discussed below, the choice of a and b values
(and hence α/β) does not affect the ability of the optimizer to converge to a plan with increase
target LETd. The assumed value of α/β = 3 Gy is our rough guess for highly radio-resistant
tumors.
2.4. Creation and assessment of biologically-optimized plans
For each patient in this study, the following three plans were created:
1. a photon IMRT plan
2. a conventional two or three-field IMPT plan
3. a five-field biologically optimized plan, using the in-house treatment planning system (TPS)
described above.
The IMRT and IMPT planning were done using a commercially-available TPS (Eclipse, Varian
Medical Systems). The number of fields used in the conventional IMPT plans is reflective of our
current clinical practice.
To create the biologically optimized plan, an Optimization Target Volume (OTV) [18], which is
akin to a planning target volume (PTV), was derived from the physician-delineated Clinical Target
Volume (CTV), and expanded by 0.5 cm to create a scanning target volume (STV). The MC was
then used to place spots inside the STV, with a hexagonal spot spacing of 0.5 cm, and the PD and
LETd maps for each spot was calculated using 10
5 proton histories. To minimize GPU memory use,
voxels receiving less than 0.5% of the maximum dose were ignored [10]. Constraints were placed
so as to maintain the OTV PD to within ∼25% of the prescription dose, while maximizing the
OTV BD. To achieve this, a lower limit was placed on the OTV BD (115% of prescription dose)
and the relative weights of the PD constraint and BD objective were adaptively changed during
each optimization step. The biologically-optimized, IMPT and IMRT plans had the same OAR
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PD constraints. The plan that best satisfies the above requirements is the ‘biologically optimal’
plan.
It should be stressed that constraints were not set on the BD for OARs, since absolute BD
values are currently not reliably calculable. Even if they were, relating the high-LET proton BD
to past photon-based experience is not trivial. In this work, the proton PD constraints for OARs
in plans 2 and 3 were derived from photon dose constraints, assuming an RBE of 1.1.
The IMPT plan was recalculated using our in-house MC to obtain its LETd and BD distribu-
tions. The percentage gains in BD and LETd in plan 3 relative to plan 2 were quantified by:
GBD = 100 ·
(
BD3
BD2
− 1
)
, GLETd = 100 ·
(
LET d3
LET d2
− 1
)
(2)
where BD2, BD3, LET d2, LET d3 are the mean target BD and LETd in plans 2 and 3. Similarly,
the increase in mean PD in plan 3 relative to plan 2 is:
GPD = 100 ·
(
PD3
PD2
− 1
)
(3)
Ideally, it is desirable to have large GBD and GLETd for a small GPD, i.e. keep the target PD as
close to the prescription dose as possible. The quantities
RD =
GBD
GPD
, RLET =
GLETd
GPD
(4)
are used to assess the gain in BD and LETd relative to the increase in PD. Although the magnitude
of GBD depends on the values of a and b in Equation 1, the optimization process does not. In
other words, the choice of a and b does not affect the ability of the in-house TPS to converge to a
biologically optimal plan.
For each patient, after optimization the BD distributions were generated using the RBE–LETd
relations from references [14, 15, 16] and Equation 1. For each RBE model, the PD and BD Dose-
Volume Histograms (DVHs) from plan 3 were compared with plan 2 to assess GBD, GPD, RD
and OAR doses. To remove dependence on the coefficients a and b, RD was calculated using the
average GBD obtained from the Carabe, Wedenberg and McNamara models. Before calculating
these metrics, all plans were normalized so that 98% of the target gets the prescription dose.
Comparisons were also made with plan 1 to gauge OAR PD sparing relative to standard IMRT
treatment. Values of GLETd and RLET were also calculated for each patient. In contrast to GBD
and RD, these are completely model-independent.
2.5. Description of test cases
This method cannot be successfully applied to all patients. Intuitively, the magnitude of GBD
depends on the number of beams, their directions and target volume. Beam directions should be
preferentially spread out isotropically around the target to facilitate LETd elevation. However, this
somewhat defeats the purpose of proton therapy, and normal tissue irradiation should be avoided
where possible. Furthermore, the contribution of any beam can be substantially reduced if an OAR
is in its path. BD escalation in large-volume targets is expected to be more difficult to achieve,
since low LETd track sections inevitably contribute to the dose.
In this study, four cases are discussed to illustrate the above points:
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A. Small thyroid tumor, OTV size: 94 cm3
B. Small thyroid tumor with OAR in the path of posterior beams, OTV size: 108 cm3
C. Large thyroid tumor, OTV size: 654 cm3
D. Small brain stem tumor, OTV size: 9 cm3
The field directions and target geometries in each case are shown in Figure 2 below. The prescrip-
tion doses for cases A-D were 66, 60, 66 and 54 Gy, in 33, 50, 30 and 30 fractions, respectively.
Cases B and C were included to demonstrate situations where our technique would not be applica-
ble. In case B the left brachial plexus (shown as the yellow contour) is in the path of the posterior
beams. Case D demonstrates the applicability of the technique to a site outside the neck region.
2.6. Multi-GPU computing
The initial PD and LETd map calculations, as well as the BD optimization, were carried out
on a remote cluster [19] using 10 to 50 NVIDIA K20X cards, depending on the target volume. A
multi-GPU system is mandatory due to the sheer scale of the initial map computations. In the
optimization stage, the workload was also divided among a large number of GPUs. Fast inter-node
communication was therefore essential for efficient data transfer. Further details of the multi-GPU
implementation are given elsewhere [10].
3. Results
Figure 2 shows the BD distributions from the MC re-calculations of the conventional Eclipse
IMPT plans (left) and our biologically optimized plans (right), for patients A to D. The BD
distributions in Figure 2 were generated using the McNamara model with α/β = 3 Gy (please see
appendix for the LETd colorwash distribution). The values of GPD, GBD from each publised RBE
model [14, 15, 16] and their averages at α/β = 3 and 6 Gy, RD, GLETd and RLET for all cases are
given in Table 1.
Patients A and D had nearly 60% increase in the mean target LETd and demonstrate the
largest values of RLET . The values of GBD and RD are model-dependent. For patients A and D
with α/β = 3 Gy, raising the target PD by 5.1 and 8.6% resulted in 11.3 and 17.3% increase in
target BD (i.e. relative gains of 2.21 and 2.02, respectively). Patients B and C had less favorable
results, the gain in BD being marginal relative to the increase in PD. The gain in mean LETd
relative to the PD increase was also much lower than for A and D. OAR DVHs for patients A
(larynx and esophagus) and D (optic chiasm and pituitary gland) from the biologically optimized,
standard IMPT and IMRT plans are shown in Figure 3. The target PD DVHs are shown in the
appendix.
3.1. Calculation time
The plan calculation time was dominated by the initial PD and LETd map calculations. The
optimization process itself typically took less than 17 minutes on the cluster. Table 2 gives the
number of beam spots covering the STV for each patient, as well as the total number of protons
in the spot maps. The total dose map processing (including the actual map calculation on the
GPU, GPU-CPU transfers, initialization and file output) and optimization times in seconds are
also given. The number of GPUs used during the optimization stage is shown in the last row.
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Figure 2: The left column shows the BD distributions (relative to the prescription dose) from the MC recalculation
of the 2-field Eclipse IMPT plans for patients A–D. The corresponding BD distributions from plans created with the
in-house optimizer are shown on the right. Arrows indicate the beam directions. The targets are delineated in red.
For patient B, the brachial plexus is delineated in yellow.
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Patient A B C D
GPD 5.1 8.2 13.6 8.6
GBD (Equation 1) 12.3 10.9 17.7 18.2
GBD (Carabe et al, α/β = 3) 12.2 9.1 17.9 18.6
GBD (Wedenberg et al, α/β = 3) 11.6 8.4 17.1 17.7
GBD (McNamara et al, α/β = 3) 10.0 8.6 16.4 15.7
GBD (average, α/β = 3) 11.3 8.7 17.1 17.3
GBD (average, α/β = 6) 10.4 8.9 16.8 15.7
RD (α/β = 3) 2.209 1.061 1.260 2.016
RD (α/β = 6) 2.029 1.082 1.236 1.823
GLETd 58.3 14.3 36.3 59.4
RLET 11.438 1.742 2.674 6.904
Table 1: Post bio-optimization metrics (defined in Equations 2–4) for cases A–D.
Patient A B C D
Target volume (cc) 94 108 654 9
Number of spots 26184 55531 121582 4255
Number of protons in dose map 2.62× 109 5.56× 109 1.22× 1010 4.25× 108
Total GPU time to create dose map (s) 18086.4 33041.4 81296.7 3497.4
Average time per proton history (µs) 6.9 5.9 6.7 8.2
Optimization time (minutes) 10.6 4.7 16.5 1.1
No. of GPUs used in optimization step 25 10 50 10
Table 2: The total number of spots and proton histories in the initial dose and LETd map calculations for each
patient are shown in the second and third rows, respectively. The net GPU processing times, average time per
proton history, optimization time and number of GPUs used during optimization are shown in rows 4, 5, 6 and 7,
respectively. All calculations were performed on NVIDIA K20X cards.
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Figure 3: Top row: larynx and esophagus DVHs for patient A. Bottom row: optic chiasm and pituitary gland DVHs
for patient B. Solid red, black and blue lines are the PD DVHs from the biologically optimized, IMPT and IMRT
plans, respectively. The proton PD has been scaled by an average RBE value of 1.1 for comparison with IMRT. The
dashed lines are the BD DVHs for the proton plans (calculated using the McNamara model with α/β = 3 Gy).
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4. Discussion
BD optimization by MC-based inverse planning has been demonstrated for two patients with
small tumor targets (A and D). For a modest rise in mean target dose, roughly twice as much
increase in BD was obtained. RD and RLET are a rough guide to the extent of the BD escalation
‘quality’. A high value of RD means that not much additional PD is required to significantly
boost the target BD, which implies that the target dose can stay relatively close to prescription.
For plans with high RD and RLET , the BD gain is a consequence of the successful and deliberate
placement of high-LET track ends inside the targets.
Compared to conventional IMPT planning, more beams were required to elevate LETd in the
target. As observed in Figure 2, the beams were not spread uniformly around the target in order
to spare normal tissue. However, a higher degree of BD escalation could have been achieved by
irradiating the opposite areas. A five-beam arrangement was used in this work because splitting
the beams (but keeping the same anatomical avoidance regions) does not result in significantly
larger RD and RLET values. For a small-target patient, the BD gain of a 10-field plan was found
to be comparable to that of a 5-field plan.
The limitations of the methods are illustrated by cases B and C. As shown in case C, achieving
BD escalation in large-volume targets is far more challenging because of the unavoidable contribu-
tion of low-LET track sections to PD. Case B has comparable volume to A, but the presence of an
OAR (the left brachial plexus) in the path of the posterior beams considerably diminished their
contribution. As a result, the remaining field directions ended up being rather similar to those in
the IMPT plan, and no significant BD boost was achieved.
Figure 3 shows that dose sparing to critical structures in the biologically optimized plans is
improved compared to both Eclipse IMRT and IMPT plans. In contrast to Eclipse, the in-house
optimization algorithm continuously drove down the dose to a given OAR even when user-defined
constraints on it were met. To achieve this, the user-defined upper constraints and their weightings
were automatically adjusted during each iteration step [10].
It might be thought that the BD gain relative to standard IMPT planning was mostly due to
the additional fields, and that a 5-field IMPT plan would demonstrate a similar level of BD gain.
In fact, BD escalation cannot be deliberately achieved if the optimizer is not explicitly instructed
to do so. To illustrate this, a 5-field standard IMPT plan was created in Eclipse for patient D,
using the same beam angles, constraints and objectives (except the BD objective, which cannot
be applied) as the biologically optimized plan. Figure 4 shows the LETd colorwash distributions
for the 5-field IMPT and biologically optimized plans in an axial cut. The central plot shows the
LETd profile across the target. Although the target PD objectives and OAR constraints were met
by both plans, the LETd distributions are very different from each other. The two peaks in the red
curve indicate that Eclipse placed high-LET proton track ends near the target edges. Conversely,
the biologically optimized plan was constructed such that protons stopped preferentially within
the target, resulting in BD escalation. Relative to the 3 field conventional IMPT plan, the values
of GPD, GBD and RD (α/β = 3 Gy) obtained for the 5-field Eclipse IMPT plan were 1.8%, 2.1%
and 1.17, showing no evidence for BD escalation.
It should be pointed out that although our LETd predictions are in very good agreement in
TOPAS, recent work [20, 21, 22] has shown that the default LETd scoring method in early TOPAS
versions (including beta-6, which we used in this work) is biased. To resolve this, the LETd scoring
method adopted in our MC will be modified to use tabulated unrestricted stopping power tables,
based on recommendations from references [20, 21, 22]. In the near future, we also plan to update
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Figure 4: LETd colorwash distributions for a standard 5-field IMPT plan (left) and our biologically-optimized plan
(right) for patient D. The LETd for voxels receiving less than 1% of the maximum dose is not shown. The central
plot shows the LETd profile across the target. The same beam angles, objectives and constraints were used in both
plans (see text).
our optimizer to use a linear-quadratic RBE model [16] instead of Equation 1. The use of a linear
RBE model in this feasibility study was purely out of simplicity, and this update is not expected
to impact our ability to achieve BD escalation.
As mentioned previously, a multi-GPU system is necessary to perform the calculations within
a clinically acceptable timeframe. Compared to a K20X, a Titan X card can process a given dose
calculation in around half the time. From Table 2, assuming the processing time to scale with the
number of GPUs, a system consisting of 24 NVIDIA Titan X cards can complete the calculations
for case A in under 30 minutes.
4.1. Feasibility trial on LETd painting
A feasibility trial on proton BD optimization is planned to start at our institution in 2016. This
trial is geared towards patients with: (a) anaplastic thyroid cancers, (b) salivary gland tumors,
(c) recurrent squamous cell carcinomas of the head and neck, and (d) recurrent glioblastomas. A
total of 24 patients will be enrolled, with 6 from each tumor category type. The tumor target
size will be critical in selecting patients. The treatment planning calculations will be carried out
on a small local cluster of 24 GPU cards, using the method described above. Candidates will be
planned using both standard IMPT and biological planning, and the treatment modality will be
chosen at the physicians discretion. The requirements for treatment using the biologically optimal
plan include large GBD, GLETd , RD and RLET values.
5. Conclusions
By taking advantage of GPU acceleration, the BD in small tumors was successfully escalated
via MC-based inverse planning optimization. In the examples given, compared to standard IMPT
planning, a modest increase in the target PD significantly raised the mean LETd and can result
in twice as much increase in the BD. The estimated BD increase depends on the LETd to BD
conversion model. The applicability of the technique was discussed. To summarize, its main
advantages are:
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• Accurate MC-based dose and LETd calculation
• Inverse planning optimization
• Clinically applicable
The main limitations are:
• Irradiation to normal tissue due to additional fields
• Not applicable to all cases, especially large target volumes
• Expected to be less robust than standard IMPT
The ability to produce such plans within a clinically acceptable timeframe opens exciting new
prospects for proton therapy.
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Figure A.5: The left column shows the LETd distributions from the MC recalculations of the Eclipse IMPT plans for
aptients A–D. The LETd distributions for the biologically optimized plans are shown on the right, in the same slices
as Figure 2 of the paper. Targets are delineated in red. For patients A and D, the mean target LETd is increased
by nearly 60%.
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Figure A.6: Target DVHs for patients A–D. Solid and dashed curves are the PD and BD DVHs, respectively. Black
curves are from the MC re-calculations of the Eclipse IMPT plans, while red curves are from the biologically optimized
plans.
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